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Abstract
Influenza A viruses are respiratory pathogens that cause seasonal epidemics with up to 500,000 deaths each year. Yet there
are currently only two classes of antivirals licensed for treatment and drug-resistant strains are on the rise. A major challenge
for the discovery of new anti-influenza agents is the identification of drug targets that efficiently interfere with viral
replication. To support this step, we developed a multiscale model of influenza A virus infection which comprises both the
intracellular level where the virus synthesizes its proteins, replicates its genome, and assembles new virions and the
extracellular level where it spreads to new host cells. This integrated modeling approach recapitulates a wide range of
experimental data across both scales including the time course of all three viral RNA species inside an infected cell and the
infection dynamics in a cell population. It also allowed us to systematically study how interfering with specific steps of the
viral life cycle affects virus production. We find that inhibitors of viral transcription, replication, protein synthesis, nuclear
export, and assembly/release are most effective in decreasing virus titers whereas targeting virus entry primarily delays
infection. In addition, our results suggest that for some antivirals therapy success strongly depends on the lifespan of
infected cells and, thus, on the dynamics of virus-induced apoptosis or the host’s immune response. Hence, the proposed
model provides a systems-level understanding of influenza A virus infection and therapy as well as an ideal platform to
include further levels of complexity toward a comprehensive description of infectious diseases.
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Introduction
Influenza A viruses continue to pose a serious threat to public
health causing three to five million cases of severe illness and up to
500,000 deaths during the annual epidemics [1]. In addition, novel
influenza strains that acquire the potential to infect and transmit
efficiently between humans can create pandemics like the 1918
Spanish Flu that killed millions worldwide [2]. Currently, there are
only two classes of direct-acting antivirals (DAAs) licensed for
influenza treatment: fusion inhibitors (adamantanes), which impair
virus entry, and neuraminidase blockers (oseltamivir and zanami-
vir) interfering with the release of progeny virus particles [3].
However, resistances against these drugs occur frequently [4,5]
urging the need for new antiviral agents [6].
In recent years, the discovery of new antiviral targets for
influenza treatment has received much attention. In particular,
compounds which interfere with host factors promise to be
effective antivirals as cellular factors are less susceptible to
mutation impairing viral escape strategies. Such compounds can,
for example, inhibit virus entry by removing cell surface receptors
as was shown for recombinant sialidases, or block viral RNA
transcription through PolII inhibition (for a detailed review of
cellular targets and their inhibitors see reference [6]). The
inhibition of essential cellular signaling cascades like Raf/MEK/
ERK signaling, NF-kB signaling, the PI3K/Akt pathway, or the
PKC signaling cascade is another promising strategy (reviewed in
[7]). Finally, viral proteins themselves are targets for antiviral
agents with new inhibitors of the viral neuraminidase, M2 ion-
channel, and polymerase on the horizon (reviewed in [8]).
With the advent of these DAAs influenza therapy has moved
beyond symptomatic treatment toward specifically targeting key
steps of viral replication. The development of new and more
potent drugs thus requires a deeper understanding of the viral life
cycle [6]. In general, the growth of influenza viruses within a host
involves at least two distinct scales: (i) the intracellular level of
infection where the virus synthesizes its proteins, replicates its
genome, and assembles new virions and (ii) the extracellular level
at which it infects new target cells and spreads throughout the
tissue. As DAAs can target both scales, understanding how these
levels interact and where to interfere to efficiently counteract an
infection is vital to the design of new antivirals.
In the past, mathematical modeling has provided valuable
insights into the kinetics of influenza A virus infection under drug
treatment ([9–13], reviewed in [14,15]). However, the majority of
studies focused exclusively on the extracellular level of infection
either neglecting or drastically simplifying intracellular events.
While such simplifications allow for the identification of critical
infection parameters from sparse data, they can influence model
predictions leading to an overly optimistic assessment of the
treatment efficiency required to suppress the infection [16]. Other
theoretical works examined how drugs affect specific replication
steps of different viruses inside an infected cell [17–19]. Yet, these
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approaches only consider a single round of infection and do not
account for the spread of the virus to new cells. Recently, Guedj
and colleagues showed that combining both levels in a model of
hepatitis C virus infection significantly improved its capability to
explain clinical observations [20,21]. However, as the authors only
included viral genome copies at the intracellular level their
approach is limited to the analysis of drugs that target genome
synthesis, degradation or packaging. Nevertheless, such studies
strongly suggest that integrating the intracellular life cycle of a
virus into a model for cell-to-cell transmission would facilitate a
systematic exploration of new drug targets. The resulting multi-
scale model can also yield a more realistic description of virus
infection [22,23] and more accurate estimates of key infection
parameters [16,20,24].
Recently, we developed a model of the complete intracellular
life cycle of influenza A virus comprising key steps from virus entry
to progeny virion release [25]. Here, we link this description to the
transmission of virus between host cells. We first show that this
integrated modeling approach successfully captures data on the
intracellular level of all three viral RNA species as well as on the
extracellular infection dynamics represented by virus titers and the
amount of infected cells. We then use the model to investigate
potential antiviral targets including the steps of virus entry, nuclear
trafficking, viral RNA and protein synthesis, and assembly/release.
We provide a ranking of these targets and show that the lifespan of
infected cells can be of particular importance for therapy success.
Finally, detailed information on the construction of the model is
provided in the Materials and Methods section at the end of this
manuscript.
Results
Multiscale model of influenza virus infection
Our description of the extracellular level of infection is based on
the classical model of viral kinetics within a host or cell population,
which accounts for uninfected cells, infected cells, and free virions
(reviewed in [14] and [15]). We augmented this framework by
explicit consideration of the number of apoptotic cells and by
modeling virus entry in more detail (Figure 1A). Once inside a cell,
the virus starts producing viral RNA and proteins. To track these
intracellular processes our multiscale model accounts for the age of
an infected cell, i.e., the time that has elapsed since its infection
(Figure 1B). The amount of each viral component inside an
infected cell over its infection age is simulated using a model of the
influenza A virus life cycle [25]. This submodel includes the
following essential features of viral replication (Figure 1C): the
production of viral mRNA and complementary RNA (cRNA)
from viral ribonucleoproteins (vRNPs), which contain the nega-
tive-strand viral genomic RNA (vRNA); the synthesis of viral
proteins; the encapsidation of newly produced cRNA and vRNA
into cRNPs and vRNPs, respectively, by the viral RNA-dependent
RNA polymerase (RdRp) and the nucleoprotein (NP); the nuclear
export of vRNPs regulated by the viral matrix protein 1 (M1) and
the nuclear export protein (NEP); and the assembly and release of
progeny virions (for further details see reference [25]). Integration
of both levels is achieved by assigning the age-dependent state of a
cell to the age-segregated cell population (Figure 1D). In the
model, intracellular replication primarily affects the extracellular
level via the virus release rate, which depends on the abundance of
viral proteins and RNA inside a cell and determines the amount of
virions released into the extracellular space. The extracellular level
in turn controls the number of infected cells and their lifespan.
Viral kinetics in the absence of drugs
To ensure an accurate calibration of both levels of the model,
we followed a two-way strategy. First, we conducted experiments
at a high multiplicity of infection (MOI), i.e., a high initial number
of virions per cell, which results in a single synchronous infection
round. This allowed us to measure the intracellular levels of the
three viral RNA species together with the number of released virus
particles and view them as the response of an average infected cell
(Figure 2A). We then performed flow cytometry of low MOI
experiments to assess the dynamics of multicycle infections where
the virus spreads throughout a cell population in successive waves
(Figure 2B). The model was fit simultaneously to both data sets
such that the intracellular part, i.e., the replication inside an
average infected cell agrees with the synchronous infection
experiments, while its combination with the extracellular model
captures the multicycle scenario. Hence, each infected cell behaves
according to the time courses shown in Figure 2A and a
population of such cells yields the dynamics in Figure 2B when
infection occurs at low MOI.
Simulation results on both levels are in good agreement with the
data showing, for instance, a rapid increase in viral mRNAs upon
infection (Figure 2A). In contrast, cRNA and vRNA synthesis does
not start until 3–4 h post infection (hpi) as the accumulation of
viral proteins is required for genome replication [26]. Between 3
and 4.5 hpi our model underestimates the cRNA level. However,
it does capture the amount of mRNA and vRNA. Since all three
viral RNA species are tightly related the model is relatively
constrained. Thus, some deviations are to be expected as the
model has to balance these time courses as well as the data on the
extracellular level. In the late phase of infection progeny vRNPs,
which provide the template for cRNA and mRNA, leave the
nucleus to be incorporated into new virus particles. This causes a
shutdown of RNA synthesis around 5–6 hpi. At the same time, the
first progeny virions leave the cell. Hence, the eclipse phase, i.e.,
the delay between infection and virus release, is approximately 6 h
(Table 1). After this delay virus production increases as more viral
components accumulate before it starts declining toward the end
of the productive infection phase when proteins and later genome
copies become limiting (Figure 1D). These intracellular dynamics
fit well with the progression of infection on the extracellular level
(Figure 2B) considering that typical errors of adherent cell
numbers are in a range of 10–20% due to variations introduced
Author Summary
Influenza A viruses are contagious pathogens that cause
an infection of the respiratory tract in humans, commonly
referred to as flu. Each year seasonal epidemics occur with
three to five million cases of severe illness and occasionally
new strains can create pandemics like the 1918 Spanish Flu
with a high mortality among infected individuals. Current-
ly, there are only two classes of antivirals licensed for
influenza treatment. Moreover, these compounds start to
lose their effectiveness as drug-resistant strains emerge
frequently. Here, we use a computational model of
infection to reveal the steps of virus replication that are
most susceptible to interference by drugs. Our analysis
suggests that the enzyme which replicates the viral
genetic code, and the processes involved in virus assembly
and release are promising targets for new antivirals. We
also highlight that some drugs can change the dynamics
of virus replication toward a later but more sustained
production. Thus, we demonstrate that modeling studies
can be a tremendous asset to the development of antiviral
drugs and treatment strategies.
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by the measurement technique, handling and trypsinization. Most
of the cells become infected between 12 and 19 hpi in the second
and third wave of infection. Virus-induced apoptosis then causes a
decline in cell numbers within the next two days. At 32 hpi, we
observe a large discrepancy between the model and the data.
However, this single time point can be regarded as an outlier since
the measured total cell concentration increased by 30% between
24 and 32 hpi (data not shown). It is highly unlikely that such an
increase occurs this late in infection. The good agreement of the
model with the infectious virus titer provides further evidence for
this. The titer shows an initial drop due to the attachment of seed
virus to cells before it increases reaching its maximum around
30 hpi.
Next, we checked the predictive capabilities of the model by
comparing it to measurements at different infection conditions that
were not used for model construction. These simulations
successfully capture the shift of infection dynamics in the presence
of higher and lower amounts of virus particles in the inoculum
(Figure 3A). In addition, the virus titer prediction for a low seed
virus concentration is in good agreement with experiments
whereas for higher MOI virus production is overestimated
(Figure 3B). We conclude that the model is in good agreement
with the intracellular and extracellular dynamics of influenza A
virus infection and can be of predictive value especially for low
MOI regimes where multiple infection rounds occur, which
resembles the in vivo situation more closely than single round
experiments that use high MOI.
A major advantage of the proposed multiscale model is that it
integrates the time course of intracellular virus replication with cell
death dynamics. This allows us to assess whether the lifespan of an
infected cell constrains virus production. From the measurements
in Figure 2B, we obtain the average lifespan of an infected cell as
25 h (Table 1). Approximately at the same time virus release
would stop due to the depletion of viral components (Figure 1D).
Nevertheless, many cells may die before the end of this productive
phase dependent on how much individual survival times vary
around the mean. Models of viral infection usually assume that the
probability of cell death is independent of time, i.e., that survival
times follow an exponential distribution (see references [24] for
more details and alternatives). Using this assumption, we find that
most cells indeed die within 25 h with more than one quarter
succumbing to apoptosis before reaching the peak in virus release
(Figure 4). Hence, cell death can affect the number of virus
particles an average cell produces.
Effects of drug treatment
Models of viral infection can be used to simulate the efficiency
of antiviral treatment. While previous studies have mostly
considered general effects of drugs on cell infection or virus
production [9,11,14], our multiscale approach can also predict
how drug interference affects the intracellular viral life cycle.
Figure 5A shows simulation results that illustrate the impact of
DAAs on the amount of virus particles an infected cell releases. In
our model, inhibitors of viral mRNA synthesis, protein translation,
Figure 1. Schematic depiction of the multiscale model. (A) The extracellular level of infection comprises the growth and death of uninfected
cells, their infection by free virions, the production of virus by infected cells, viral clearance/degradation, virus-induced apoptosis, and the lysis of
apoptotic cells. (B) Infected cells are further segregated according to their infection age, i.e., the time that has elapsed since their infection. (C) The
intracellular state of an infected cell is simulated using the model of influenza virus replication by Heldt et al. (see text and reference [25] for details).
(D) Both levels are coupled via the age-dependent virus production rate, which depends directly on the internal state of a cell and determines the
number of virions released into the extracellular space.
doi:10.1371/journal.pcbi.1003372.g001
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and virus assembly/release are highly effective in reducing virus
production even at low drug efficacy. Note that antivirals usually
show a maximum efficacy above 90% [9,10,27]. At these levels,
inhibitors of mRNA splicing, cRNA/vRNA synthesis, and nuclear
export are also very successful. Intriguingly, inhibition of the two
steps of RNA replication can, however, lead to an increase in virus
release for low-efficacy drugs. A similar result can be observed
when targeting M1 binding and the encapsidation of viral RNAs
by NP. Figure 5B shows the simulated time courses of different
viral components in response to selected low-efficacy drugs. As
expected, the inhibition of viral transcription leads to lower
mRNA levels, which impairs protein synthesis and virus release
(Figure 5B upper panel). We also observe a minor increase in
cRNAs and vRNAs during the early phase of infection due to
lower M1 protein levels. Based on experimental evidence [28–30],
M1 acts as a negative regulator of cRNA and mRNA synthesis in
our model [25]. Together with NEP, it binds to vRNPs controlling
their nuclear export. Once outside the nucleus, vRNPs can no
longer serve as templates for the two positive-strand RNAs. In
addition, M1 proteins fulfill a second role during virus assembly
where they form the inner hull of virus particles as their most
abundant viral component [31]. Hence, inhibition of particle
assembly/release also results in higher M1 levels, a stronger
negative regulation of RNA synthesis, and lower RNA levels
besides reducing virus release (Figure 5B middle panel). This type
of regulation also causes the increase in virus titers seen upon weak
inhibition of cRNA synthesis (Figure 5B lower panel). The
reduction in RNA levels in the early phase of infection leads to
a lower abundance of M1 proteins. The resulting lack of inhibition
allows a faster synthesis of RNAs during later stages and
consequently a higher rate of virus release. Since the release of
virions further drains the pool of M1 proteins, our model predicts
a sustained production of virus particles for these drug efficacies.
Figure 5B highlights an interesting aspect of viral replication.
There may be regimes where a higher overall number of viruses
can be produced at the expense of an early virus release. Yet, such
an advantage would clearly depend on the lifespan of an infected
cell and on whether cell death by virus-induced apoptosis or the
immune response shortens it (Figure 6). While the inhibition of
cRNA synthesis may lead to higher titers in our system, drug
treatment has hardly any influence on virus production when
apoptosis occurs at twofold of its estimated rate (Figure 6C 16–
26). For an even shorter lifespan of infected cells the antiviral may
be deemed effective reducing particle production to half its pre-
treatment level (Figure 6C 46). Hence, the effect of a drug on viral
replication has to be judged with respect to cell death dynamics to
correctly evaluate treatment potential.
Apart from reducing particle production, antivirals can also
delay the spread of the virus providing time for the immune system
to counteract infection. Figure 7A illustrates the evolution of virus
titers in a susceptible host cell population under simulated drug
treatment. Again, inhibitors of viral RNA and protein synthesis
almost completely suppress viral replication. Therefore, these
drugs protect most of the host cells from infection (Figure 7B).
Nevertheless, a few cells become infected and produce virus
causing the titer to only slowly decline. In contrast, drugs targeting
Figure 2. The multiscale model captures the intracellular and extracellular level of infection. Curves represent model fits to experimental
infections of MDCK cells with influenza A/PR/8/34 (H1N1) depicted by symbols. (A) Levels of vRNA, cRNA (dashed, %) and mRNA (solid, #) of
segment 5 (encoding NP) and the amount of virus particles produced by an average infected cell in a synchronous, single round infection experiment
(MOI = 6). Particle numbers correspond to the amount of hemagglutinating virus particles and were calculated from virus titer measurements by HA
assay using Equation (12). Bars indicate the standard deviation of three independent experiments (two for the 9 and 10 hpi measurements). (B)
Concentration of uninfected (solid,#), infected (dashed,%) and apoptotic (dash-dotted, D) cells and infectious virus titer during multicycle infection
(MOI = 0.1). Time courses were adopted from Isken et al. and are representative of three independent experiments [35].
doi:10.1371/journal.pcbi.1003372.g002
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virus entry, i.e., fusion, endocytosis and binding to the cell surface,
are less successful in decreasing peak titers but delay infection by
up to 50 h. However, they do not prevent the cell population from
becoming infected. Note that, in this scenario, peak titers are
primarily constrained by the number of available cells. When cells
are depleted virus production ceases and titers decrease with the
rate of viral clearance.
Discussion
Viral infections cover several scales, a form of complexity that
computational modeling is poised to address [32]. In this study, we
developed a model that integrates the main stages of influenza A
virus infection within a host: the intracellular replication of the
virus and its extracellular transmission to new host cells. This
multiscale approach accurately captures a variety of in vitro
measurements, provides insights into virus growth across different
scales, and aides the development of DAAs.
The limited quantity and diversity of experimental data still
represents a significant bottleneck for models of extracellular viral
kinetics and their validation [15]. A promising approach to close
this gap is to incorporate detailed information on the intracellular
viral life cycle. Our model of virus replication was previously
validated against a variety of experimental studies including data
on virus binding, fusion, RNA synthesis, and regulation by viral
proteins [25]. In combination with the quantitative RNA levels
presented here, it provides a detailed picture of intracellular events
and their impact on virus production. For instance, it yields a delay
of 6 h between infection and virus release and suggests that virus
production increases for another 7 h as viral components
accumulate. While the length of the eclipse phase is in good
agreement with estimates from other modeling studies (7 h for
MDCK cells in bioreactors [33], 0.22–6 h for cultivations in a
hollow-fiber system [11] and 6 h for human infection [9]),
previous models have assumed that virus production proceeds at
a constant rate in the productive phase. Since simulations are quite
sensitive to such assumptions [16,24], multiscale modeling can
lead to more realistic estimates of key infection parameters [20],
which were shown to greatly support the design of antiviral
Table 1. Parameter estimates from data in Figure 2.
Parameter Value 95% CIa








































tapo hð Þe 24.9 14.3–36.3
teclipse hð Þf 5.7 5.1–6.5
a95% confidence intervals provided by the quantiles Q0.025 and Q0.975 of 2000
bootstrap replicates [56].
bOne is the upper bound of this parameter as no more cells can become
infected than virions fuse with endosomes.
cEstimates reached the lower and upper parameter bounds.
dSynthesis rate of an mRNA of average length. In the model, transcription is
length dependent with a rate of 8.536105 nucleotides/h (see reference [25] for
details).





which includes the eclipse phase.
fThe end of the eclipse phase was defined as the time when the virus release
rate rRel tð Þw1 virion=h. Note that this includes the steps of virus entry. The
delay between fusion and virus release is only 2 h.
doi:10.1371/journal.pcbi.1003372.t001
Figure 3. Model predictions reproduce data for different
infection conditions. The model fit from Figure 2 (dashed, %) was
used to predict the percentage of uninfected cells (A) and the infectious
virus titer (B) for infections at an MOI of 1024 (solid,#) and of 3 (dash-
dotted, D), respectively. These predictions were compared to data sets
not used for model construction. Measurements were adopted from
Isken et al. and are representative of three independent experiments
[35].
doi:10.1371/journal.pcbi.1003372.g003
Figure 4. Cell death constrains virus production. Survival
probability of an infected cell (solid) and virus production rate over
the infected cell age neglecting cell death (dashed) and considering cell
death (dash-dotted).
doi:10.1371/journal.pcbi.1003372.g004
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treatment [34].
We estimate the lifespan of an infected cell as 25 h (including the
eclipse phase), which is in the range of other studies (reviewed in
[15]). Virus production would cease around the same time due to
the depletion of viral components in the cell. Nevertheless, most of
the cells in our simulations die before the end of the productive
phase as survival times vary significantly around the mean.
Following the majority of models for viral infection, we assumed
an exponential distribution of the survival time. Yet, a recent study
suggested that other distributions may be more appropriate to
capture viral kinetics [24]. In principle, our model is ideal to
accommodate such assumptions since the apoptosis rate can be
Figure 5. Inhibition of viral RNA synthesis, translation, or assembly/release efficiently impairs virus production. (A) Simulated impact
of drugs targeting the indicated steps of intracellular virus replication with varying efficacy. Colors indicate the fold change in the total number of
virus particles an average infected cell produces over its lifetime compared to the drug-free regime. Numbers in circles correspond to the examples
shown in B. (B) Time courses of selected viral components during drug treatment with 50% efficacy. Columns correspond to components depicted in
the scheme. Dashed and solid lines are time courses in the absence and presence of drugs, respectively. All components were normalized to their
maximum in the drug-free regime.
doi:10.1371/journal.pcbi.1003372.g005
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chosen freely as a function of the infected cell age. However, our
simulations (Figure 2) and data on apoptosis induction during
single-cycle infections [35] do not justify more complex approaches.
Although in good agreement with the data, our simulations
underestimate the intracellular level of cRNA between 3 and
4.5 hpi. Yet, both the mRNA and vRNA level are captured nicely.
This might be due to a differential regulation of viral transcription
and replication unaccounted for in the model so far. Such control
could, for instance, be mediated by NP (reviewed in [36]), NEP
[37] or small viral RNAs [38]. However, the contribution of these
mechanisms is still a matter of controversial debate and
quantitative data is lacking preventing us from incorporating this
type of regulation in the model. We, thus, chose to keep our
mathematical framework as simple and constrained as possible.
Nevertheless, the model simultaneously captures a rich pool of
data indicating that it incorporates the key steps of in vitro influenza
virus infection.
When testing the model against data for different infection
conditions that were not used for construction, we also noticed an
overestimation of virus production for high MOI. In our model,
peak virus titers primarily depend on the initial cell concentration,
which was comparable in the three experiments and the number
of virions each cell produces. The cell-specific virus yield follows
from the intracellular replication dynamics and the lifespan of an
infected cell (i.e. the yield equals the integral under the dash-dotted
virus production curve in Figure 4). Hence, the observed decrease
in virus production at high MOI can be explained in two ways. On
the one hand, factors present in the inoculum may impair
intracellular virus replication reducing the rate of virus production.
Defective interfering particles could be such factors [39]. On the
other hand, the inoculum can contain substances such as
interferons that may reduce the lifespan of an infected cell by
increasing apoptosis induction [35]. Experimental work is in
progress to discriminate between these two hypotheses.
For the construction and calibration of our model, we mostly
relied on cell culture experiments due to the limited diversity of
available in vivo data. Currently, virus titers are the type of data
most frequently used for in vivo models (reviewed in [14]) as they
are easily attainable from infected individuals and animals. In
principle, four parameters are sufficient to describe such titer
curves constraining the level of detail one can incorporate into a
mathematical model [24]. In contrast, in vitro systems provide
access to a variety of information like the number of available cells,
their infection status or the intracellular level of viral RNAs. This
wealth of data was a prerequisite for the development of our
multiscale model. However, now that the model has been
established future studies may want to implement modifications
to closer resemble the in vivo situation. For instance, the growth
and death of uninfected cells is usually neglected in acute infection
models as target cell dynamics are assumed to be slow compared
to infection [14]. Furthermore, virus loss in the lung is caused by
active processes such as phagocytosis and mucociliary clearance as
opposed to degradation in cell culture experiments and may,
hence, be faster. However, the most prominent feature of in vivo
infections our model is currently lacking is the immune system.
Although a number of models were proposed that incorporate an
immune response none of them agreed completely with the variety
of experimental data available [40]. Implementing an adequate
description of the immune response, thus, remains one of the
major challenges in viral kinetic modeling today [14,40–42].
Modeling intracellular replication in detail allowed us to
simulate the effect of DAAs on the amount of virions an average
infected cell produces. Given a drug efficacy above 90%
inhibitors of viral transcription, replication, protein synthesis,
nuclear export, and assembly/release proved to be most
successful in mitigating replication. Indeed, antivirals targeting
virus release in the form of neuraminidase inhibition are widely
used in influenza treatment today. To exploit this target in the
future new compounds are, however, required as the emergence
of drug-resistant strains is on the rise [8]. Inhibitors of the viral
polymerase are a promising alternative. During viral replication
polymerases engage in an autocatalytic reaction where they
synthesize cRNA from vRNA and vice versa. In addition, they
transcribe the viral genome into mRNAs for new polymerases.
Interrupting this positive feedback has detrimental consequences
for all major viral components in our model. In agreement with
this, compounds which specifically inhibit viral transcription
efficiently impair influenza A virus replication in cell culture and
mice [43]. Similarly, favipiravir (T-705), an inhibitor of influenza
virus RNA polymerase activity [44], is potent against influenza
viruses in vitro and in vivo [45,46] and has entered clinical trials
recently [47] demonstrating the potential of viral RdRps as drug
Figure 6. Cell death affects therapy success. (A) Virus production rate over the age of an infected cell in the absence of drugs (solid) and during
inhibition of cRNA synthesis with 50% efficacy (dashed). (B) Different survival probabilities for an infected cell assuming that virus-induced apoptosis
occurs with the rate estimated from data in Figure 2B (16, solid line) or at twofold (26, dashed line) and fourfold (46, dash-dotted line) its rate. (C)
Total amount of virus particles released by an infected cell considering the combination of different production rates and survival probabilities.
doi:10.1371/journal.pcbi.1003372.g006
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targets. Our model could be used to test different dosing regimes
and support such clinical trials.
In other studies, interference with the assembly of viral
polymerase complexes by 25-amino-acid peptides [48] or small
molecule inhibitors [49] has been shown to inhibit viral
replication. In contrast, RdRp formation has hardly any
influence on virus production in our model unless the drug
efficacy well exceeds 99%. This discrepancy most likely
originates from the kinetics of polymerase assembly in our
model. Due to the lack of quantitative data, we assumed that
polymerases form from their three subunits according to mass
actions kinetics [25]. Rather than the formation itself subunit
availability represented the kinetic bottleneck for RdRp assem-
bly in simulations. In light of the above mentioned experimental
studies, future models may need to revise this assumption if
polymerase assembly is at the focus of investigation. Reconciling
model predictions that are initially inconsistent with data
provides an ideal opportunity to also refine our understanding
of the underlying biology but it requires experiments specifically
designed to resolve the discrepancy.
Instead of reducing peak virus titers, our model predicts that
inhibitors of virus entry mainly delay in vitro infection, which is in
agreement with previous studies [11]. This is because they only
decrease the infection rate of cells instead of impairing the
processes responsible for viral component production resulting in
similar cell-specific virus yields. The treatment success of such
inhibitors may, hence, depend on mechanisms, which take
advantage of the delay and clear infection.
Intriguingly, some of our simulations yield regimes where
treatment can also lead to an increase in virus production at the
expense of early virus release. From an evolutionary perspective this
regime might not be beneficial as faster growing strains would out-
compete such variants. However, during treatment it may,
nevertheless, occur. We show that the lifespan of an infected cell
determines whether a slower but more efficient virus production
leads to higher titers. An antiviral treatment that was rejected based
on the survival times of infected cells in cell culture may thus even be
successful when lifespans are shorter. In vivo, the latter is indeed very
likely as the immune response increases cell death rates [42,50].
Also, virus strain-dependent factors such as the expression of the
Figure 7. Inhibition of virus entry delays infection. (A) Simulated effect of drugs targeting the indicated steps of virus infection with an efficacy
of 95%. Colors indicate the log10 virus titer. Numbers in circles correspond to the examples shown in B. (B) Concentration of uninfected target cells
and virus titer in the absence of drugs (solid line) and during treatment with inhibitors of virus fusion (dashed) and mRNA synthesis (dash-dotted) at
95% efficacy.
doi:10.1371/journal.pcbi.1003372.g007
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PB1-F2 protein can lead to faster cell death [51]. Screening
approaches for antiviral compounds may, hence, benefit from using
conditions that mimic the cell survival times observed in vivo.
In summary, we have developed a multiscale model of in vitro
influenza A virus infection which integrates the intracellular level
of viral replication and the extracellular level of cell-to-cell
transmission. We are optimistic that such models will contribute
to the development of antiviral drugs, support clinical trials and
provide a platform for the establishment of more detailed infection
models in the future. To achieve this goal, next-generation models
will need to incorporate the immune response, pharmacokinetics
and comprehensive information on virus-host interactions. Multi-
scale modeling provides an ideal framework for such an endeavor
as diverse cellular processes can be simulated individually and
incorporated as separate modules into a unifying framework.
Methods
Model of the extracellular level
We used an age-segregated infection model for adherent cells,
which follows from the general population balance [23], to
describe the dynamics of uninfected target cells (T ), infected cells
(I ), and their apoptotic counterparts Ta and Ia, respectively
dT
dt











































where uninfected cells grow with specific rate m or undergo
apoptosis with rate k
Apo
T . Growth can occur with a maximum
specific rate mmax to a maximum concentration of Tmaxcells
assuming that all non-apoptotic cells occupy a finite surface area.
The infection rate is denoted rInf and will be discussed at the end
of this section. In Equation (2), infected cells have the age t and
undergo virus-induced apoptosis with an age-dependent rate
k
Apo
I tð Þ. Since infection creates cells with age zero, we obtained
the boundary condition I t,t~0ð Þ~rInf T . Apoptotic target cells in
Equation (3) can either become infected or undergo cell lysis with
rate kLys. The same lysis rate is used for apoptotic infected cells.
Assuming that there are no infected cells in the beginning
(I t~0,tð Þ~0), we can rewrite Equation (2) in terms of an
algebraic equation
I t,tð Þ~ r








I t,tð Þdt gives the number of infected cells with age
between t1 and t2. Equation (5) illustrates that cells which have
age t at time t were infected at time t{t. The integral term
accounts for cell loss due to apoptosis. Using Equation (5) instead
of Equation (2), thus, allows us to track the infection front
precisely.
The equation for infectious virus particles (V ) in the extracel-



























where rRel denotes the age-dependent virus production rate. We
assumed that virions are degraded or cleared with rate k
Deg
V . The
binding of virus particles to target cells was modeled as described
before [25]. In brief, we considered two types of binding sites (Bn):
high-affinity (n~hi) and low-affinity (n~lo) sites. The virus
attaches to or dissociates from these sites with rates kAttc,n and
kDisn , respectively, whereby the latter rate follows from the
equilibrium constant kEqc,n. The concentration of free binding sites
was calculated from their total number per cell (Btotn ), the
concentration of target cells, and the concentration of attached
virus particles (VAttn ). In this notation each virion occupies one
binding site. Note that we did not consider binding to infected cells
as neuraminidase expression on the cell surface limits superinfec-
tion [52].
In order to account for drug effects on virus entry, we defined
equations for the concentration of attached virions (VAttn ) on the
surface of target cells (considering both T and Ta) as well as for





















where kEn and kFus denote the endocytosis and fusion rate,
respectively. The first two terms in Equation (7) account for virus
binding and dissociation as well as for endocytosis. The last term
quantifies the loss of virions with cells that leave the compartment
of interest, i.e., with cells leaving the population of target cells by
infection or cell lysis with rate rInf and rLys, respectively. Equation
(8) accounts for the endocytosis of virions attached to both types of
binding sites, the fusion of virions with the endosomal membrane,
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and again the loss of particles due to infection and lysis of target
cells.
Since we consider a cell ‘infected’ as soon as viral genome copies
enter its cytoplasm, the infection rate rInf follows from the fusion












where FInf corresponds to the number of cells which become
productively infected upon the fusion of one virion. This number
cannot exceed one but may become lower if several virions are
required to cause productive infection. While the first part of
Equation (9) represents the number of cells that become infected
per hour, the fraction serves two purposes: substituted in
Equations (7) and (8) it provides the number of viruses per target
cell and in Equations (1) and (3) it yields the fraction of non-
apoptotic and apoptotic target cells, respectively, to total target





Model of the intracellular level
The intracellular level of infection was essentially modeled as
described before [25]. In brief, a set of ordinary differential
equations was used to simulate virus entry, viral RNA and protein
synthesis, and virus assembly. In contrast to the original
description, we modified the equation of the virus release rate












j[ RdRp, HA, NP, NA, M1, M2, NEPf g,
where release depends on the abundance of progeny vRNPs in the
cytoplasm (Vp
cyt
M1) and structural viral proteins (Pj ) with KVrel
denoting the number of virus particles for which components must
be present in order to reach half the maximum release rate. In its
new form, rRel can only increase to a maximum rate of kRel
assuming that there is only a limited number of host factors
available for virus budding. This change was implemented to
avoid unrealistically high virus production rates that occurred in
some treatment regimes.
For simulations in Figure 1D and Figure 2A, the complete
intracellular model was used as described above. However, when
coupling the model to the extracellular level, we neglected virus
entry and initialized the model with a complete set of eight vRNPs
in the cytoplasm. Attachment, endocytosis, and fusion were
considered at the extracellular level instead (Equations (7) and (8)).
Integrated simulation approach
In order to ease the computational burden and allow for a more
intuitive interpretation of simulation results, we assumed that the
extracellular level has little or no influence on intracellular events,
i.e., that each infected cell behaves the same independent of the
time of infection and the extracellular environment. As shown by
Haseltine and colleagues, this assumption permits the selective
decoupling of both levels and reduces the model’s complexity
significantly [23]. Hence, we could first simulate intracellular virus
replication to calculate the virus release rate rRel as a function of
the infection age t. This rate was then used in Equation (6) to
simulate the extracellular level.
The intracellular submodel was solved numerically with the
CVODE routine from SUNDIALS [53] on a Linux-based system.
Model files and experiments were handled with the Systems
Biology Toolbox 2 [54] for MATLAB (R2010b The MathWorks
Inc.). We then used Euler’s method with a step size of Dt~0:05 h
to solve the extracellular model (Equations (1) and (3)–(8)). The
integrals in Equations (1), (4) and (6) were approximated in each
step by substituting Equation (5) for I t,tð Þ and using the rectangle
rule with a step size of Dt~0:05 h. To further reduce computa-
tional costs, the integral in Equation (5) was evaluated prior to
simulation following the same approach. The method was checked
for numerical accuracy against simulations using smaller step sizes
and by comparison to a discrete version of Equation (2) with a
large number of age classes.
Table S1 lists the initial conditions of all presented simulations.
Parameters of the intracellular model can be found in Table S2
and Table S3 shows parameter values for the extracellular model.
Table 2. Primer sets for the reverse transcription and real-time RT-qPCR.
Target Purpose Primer Name Sequence (59-39) Position (nt)
mRNA reverse transcription Oligo tagdTRT rev GTAAAACGACGGCCAGTTTTTTTTTTTTTTTTT polyA tail
real-time RT-qPCR Seg 5 Realtime for GGAAAGTGCAAGACCAGAAGAT 1388–1410
real-time RT-qPCR mRNA tagRealtime rev GTAAAACGACGGCCAGT tag sequence
cRNA reverse transcription Seg 5 tagRT rev GCTAGCTTCAGCTAGGCATCAGTAGAAACAAGGGTATTTTTCTT 1541–1565
real-time RT-qPCR Seg 5 Realtime for GGAAAGTGCAAGACCAGAAGAT 1388–1410
real-time RT-qPCR cRNA tagRealtime rev GCTAGCTTCAGCTAGGCATC tag sequence
vRNA reverse transcription Seg 5 tagRT for ATTTAGGTGACACTATAGAAGCGAGTGATTATGAGGGACGGTTGAT 192–215
real-time RT-qPCR Seg 5 Realtime rev CGCACTGGGATGTTCTTC 282–300
real-time RT-qPCR vRNA tagRealtime for ATTTAGGTGACACTATAGAAGCG tag sequence
doi:10.1371/journal.pcbi.1003372.t002
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Parameter estimation
Model parameters were estimated by fitting the complete
intracellular submodel (including the equations for virus entry) to
experimental virus titers per cell and the levels of vRNA, cRNA
and mRNA measured during high MOI infection (Figure 2A).
Simultaneously, the reduced model (excluding virus entry) was
coupled to the extracellular equations using the same parameters
and the complete multiscale model was fit to the time courses of
uninfected and infected cells, their apoptotic counterparts, and the
virus titer during low MOI infection (Figure 2B). Estimation was
performed using the fSSm algorithm for stochastic global
optimization [55]. In particular, the algorithm was used to
simultaneously minimize the least squares prediction error of all
measured state variables, whereby the error of each variable was
normalized by its respective maximum measurement value (e.g.
the deviation between measured and simulated vRNA level was
weighted by the maximum of the measured vRNA level). The
summed errors of the intracellular and extracellular part of the
model were then divided by the number of measurements,
respectively, and added to attain an overall measure of fit quality.
Since experiments indicated that real-time RT-qPCR detects free
viral RNAs from the seed virus supernatant, which may adhere to
cells but cannot enter them, we applied the first measurement
value as an offset to all simulation values of viral RNAs. Bootstrap
confidence intervals [56] were determined considering the
standard deviations in Figure 2A as well as a 20% error for cell
counts and 0.3 log for virus titers in Figure 2B.
Simulation of drug treatment
In order to simulate drug treatment with efficacy e, parameters
in the model which correspond to the drug’s target (Table S4) were
perturbed by 1{eð Þ. Treatment was assumed to occur at constant
efficacy starting from 0 hpi. For results in Figure 5A, the reduced
intracellular model was simulated first to determine the virus
release rate rRel . The total amount of virus particles produced by
an average infected cell over its lifetime (VReltot ) was then calculated














Cell culture and virus infection
For single round infections (Figure 2A), adherent MDCK cells
(ECACC No. 84121903) were grown in GMEM (GIBCO)
supplemented with 10% fetal calf serum (FCS) (PAN Biotech)
and 1% peptone (Lab M) using T175 flasks and incubated at 37uC
under a 5% CO2 atmosphere to maintain pH 7.2. One day before
infection, cells were washed twice with phosphate buffered saline
(PBS), detached and counted with a Vi-CELL XR (Beckman
Coulter). Subsequently, 1.756106 cells were seeded into 35 mm
dishes. Infection was performed using influenza A/Puerto Rico/
8/34 (Robert Koch Institute,#3138) with a seed virus preparation
containing 1.236108 infectious virus particles per mL. Prior to
infection, cells were washed twice with PBS and virus was added at
a multiplicity of infection (MOI) of 6 in 250 mL serum-free virus
maintenance medium (GMEM, GIBCO) containing 1% peptone
(Lab M) and 5 units/mL trypsin (GIBCO). Dishes were incubated
for 30 minutes at 37uC and 5% CO2 atmosphere before cells were
washed once with PBS and 1 mL virus maintenance medium was
added.
To correctly account for the loss of viral components due to
virus release, the total amount of virus particles leaving an average
infected cell was determined using the hemagglutination assay as
described previously by Kalbfuss et al. [57]. Titer measurements in
log10 HA units per test volume (log HAU/100 mL) can be
converted into hemagglutinating particles per mL by
cvirus~2|10
7:10 logHAU=100 mLð Þ, ð12Þ
assuming that at least one virus particle per erythrocyte (26107
cells/mL) is required to cause agglutination [58].
For detailed information on the multicycle experiment
(Figure 2B), the reader is referred to reference [35] from which
the measurements were adopted. In brief, adherent MDCK cells
were cultivated to confluence in T25-flasks and washed with PBS
prior to infection followed by addition of serum-free virus
maintenance medium (GMEM, GIBCO) containing 1% peptone
(Lab M) and 5 units/mL trypsin (GIBCO). Subsequently,
influenza A/Puerto Rico/8/34 was added at an MOI of 1024,
0.1 and 3. For each time point one T-flask was harvested and
adherent cells were trypsinized and pooled with the cells from the
supernatant. Aliquots of 106 cells were fixated with 1% parafor-
maldehyde (Sigma-Aldrich) and 70% ethanol (Carl Roth) and
stored at 220uC. Double staining for infection status and
apoptosis was performed using a fluorescein isothiocyanate
(FITC)-labeled anti-NP mAb (AbD Serotect) and a terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay kit (Roche Diagnostics), respectively. Measurements were
collected using an Epics XL flow cytometer (Beckman Coulter). In
addition to flow cytometry, the infectious virus titer was measured
from the supernatant of T-Flasks using a TCID50 assay as
described before by Genzel and Reichl [59].
Real-time RT-qPCR
To extract viral RNAs, cells were washed once with PBS, lysed
and scraped from the dish. Lysates were stored at 280uC. RNA
was extracted using ‘‘INSTANT Virus RNA’’ (Analytik Jena)
according to the manufacturer’s instructions and stored at 280uC.
For the real-time RT-qPCR assay, priming strategies for the
differentiation of viral RNA species were adapted from Kawakami
et al. [60]. In brief, polarity specific and tagged primers (Table 2)
were used in reverse transcription as follows. 1 mL of RNA extract
was mixed with 1 mL primer (1 mM for cRNA and vRNA; 10 mM
for mRNA), 1 mL dNTPs (10 mM each) and filled up to 14.5 mL
with nuclease-free water. The mixture was incubated at 65uC for
5 min and subsequently cooled to 40uC for mRNA and 55uC for
cRNA and vRNA. Afterward, the reaction mixture (4 mL
56Reaction Buffer, 0.5 mL Maxima H-Minus Reverse Transcrip-
tase (200 U/mL) (Thermo Scientific) and 1 mL nuclease-free water)
was added. After incubation at 60uC for 30 min the reaction was
terminated at 85uC for 5 min.
Additionally, a 10-fold dilution series of the corresponding RNA
reference standards (5?1027 to 5 ng) each containing 350 ng
cellular total RNA was reverse transcribed. Subsequently, the RT
reaction was diluted to a final volume of 100 mL. Concentration of
viral RNA was determined in molecules per cell using ‘‘Rotor-
Gene SYBR Green PCR Kit’’ (Qiagen) and Rotor-Gene Q real-
time PCR cycler (Qiagen). 4 mL of the diluted cDNA were mixed
with 1 mL primer set and 5 mL reaction mixture. The cycle
conditions of the real-time PCR were 95uC for 5 min followed by
40 cycles of 95uC for 10 sec and 60uC for 20 sec. Finally, a
melting curve from 65uC to 90uC was performed. The concen-
tration of viral RNA was calculated based on the RNA reference
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standards with linear regression (Ct-value against log10 of number
of molecules). The number of viral RNA molecules (nmolecules) was








where mtemplate (ng) is the mass of the template, k~340 Da=bp
denotes the average mass of one base, and N{1A (mol
21)
corresponds to the Avogadro constant. The number of RNA
molecules was then related to the number of cells (ncells (cells)) to
calculate the abundance of viral RNAs per cell (SQsample







using the coefficient for dilution of RT reaction (FRT ) and the
volume of RNA eluate (Veluate (mL)).
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